METHODS	HIV-infected women with central adiposity and HIV-1 RNA < 50 HIV-1 RNA copies/mL continued their thymidine-sparing nucleoside reverse transcriptase inhibitor ( NRTI ) backbone and were randomized to switch to open-label RAL at week 0 ( immediate ) or 24 ( delayed ) .\